SCHEMBL4907974

SCHEMBL4907974

COc1ccc(CCCl)cc1Cc1cc(CCCl)ccc1OC

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.57
ATM Q13315 2/20 0.47
POLB P06746 1/20 0.47
CA2 P00918 1/20 0.47
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2D6 P10635 1/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13694250 0.93 AKT1 (0.56) AKT1ATMPOLBCA2KDM4E
SCHEMBL14270293 0.92 AKT1 (0.51) AKT1ATMPOLBCA2KDM4E
SCHEMBL11290729 0.83 GABRA1 (0.55) AKT1ATMPOLBCA2KDM4E
SCHEMBL1332082 0.82 ATM (0.66) ATMPOLBCA2KDM4ECYP1A2
SCHEMBL4615833 0.82 AKT1 (0.45) AKT1ATMPOLBKDM4ECYP1A2
SCHEMBL4672811 0.79 ATM (0.45) ATMPOLBCA2KDM4ECYP19A1
SCHEMBL8938305 0.78 TSHR (0.69) CYP1A2CYP3A4CYP19A1GAATSHR
SCHEMBL14144881 0.78 MAPT (0.51) ATMPOLBKDM4ECYP1A2CYP3A4
SCHEMBL28186288 0.78 GAA (0.67) ATMPOLBCA2KDM4ECYP1A2
SCHEMBL30135970 0.78 GAA (0.67) ATMPOLBCA2KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221702-A1 COMPOUNDS IMPERIAL INNOVATIONS LIMITED (GB) 2009-09-03 US disclosed
US-20080039527-A1 Calixarenes as Inhibitors of Protein Kinase B IMPERIAL COLLEGE INNOVATIONS LTD. 2008-02-14 US disclosed
US-20080039527-A1 Calixarenes as Inhibitors of Protein Kinase B IMPERIAL COLLEGE INNOVATIONS LTD. 2008-02-14 US disclosed
US-20080039527-A1 Calixarenes as Inhibitors of Protein Kinase B IMPERIAL COLLEGE INNOVATIONS LTD. 2008-02-14 US disclosed
EP-1687255-A2 CALIXARENES AS INHIBITORS OF PROTEIN KINASE B Imperial College Innovations Limited (GB) 2006-08-09 EP disclosed
WO-2005023744-A2 CALIXARENES AS INHIBITORS OF PROTEIN KINASE B IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039527-A1 Calixarenes as Inhibitors of Protein Kinase B CAMK2B, PNCK, CAMK1 AKT1 25/4885ATM 766/4885POLB 2094/4885
US-20090221702-A1 COMPOUNDS NCEH1, NME2, HRH3 AKT1 33/4885ATM 2486/4885POLB 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.